SMShariq Madha

Shariq Madha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shariq Madha has a total of 121 co-authors. Here are the top co-authors by number of shared publications:

  • Ramesh A. Shivdasani

    Department of Medical Oncology and Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA

    8 shared publications
  • Unmesh Jadhav

    Department of Medical Oncology and Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, USA

    6 shared publications
  • Alessia Cavazza

    Molecular and Cellular Immunology Section, Department of Infection, Immunity & Inflammation, Great Ormond Street Institute of Child Health, University College London, London WC1N 1DZ, UK

    3 shared publications
  • Kai Wucherpfennig

    Department of Molecular Oncology, Genentech, South San Francisco, CA 94080, USA; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA 02215, USA

    3 shared publications
  • Elisa Manieri

    Department of Medical Oncology and Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA

    2 shared publications
  • Frederic J. de Sauvage

    Department of Molecular Oncology, Genentech, South San Francisco, USA

    2 shared publications

Latest Publications

  • Open Access

    Subepithelial myofibroblasts enhance stem cell regeneration after intestinal epithelial damage

    by Neil McCarthy, Camila Mendez Jimenez, Guodong Tie, Gizelle McCarthy, Shariq Madha-Krause, Ruiyang He, Ramesh A. Shivdasani

    When intestinal stem cells (ISCs) are damaged, other epithelial cells de-differentiate to restore the ISC compartment. Immune, nerve and lymphatic endothelial cells contribute signals that promote this response, but it is unclear whether or how the native mesenchymal niche senses and responds to ISC loss. In homeostasis, trophocytes and smooth muscle beneath intestinal crypts secrete BMP inhibitors (BMPi) and R-spondins to foster ISC self-renewal, whereas sub-epithelial myofibroblasts (SEMFs) concentrated at crypt tops promote differentiation through bone morphogenetic proteins (BMPs). We assessed transcriptional responses in mouse sub-epithelial populations after ablating ISCs with whole-body irradiation and treating Lgr5DTR mice with diphtheria toxin. More than any other cell type, SEMFs modulated expression of genes related to ISC expansion. However, the BMPi gene Smoc1 and non-canonical Wnt signals, both expressed in SEMFs after whole-body irradiation, were dispensable for ISC restoration. Instead, SEMFs appear to support ISC regeneration through factors that are not induced by ISC attrition per se but by local inflammation. These findings reveal unexpectedly limited transcriptional modulation of the native niche after ISC losses and context-dependent signaling functions for SEMFs.

  • Crypt density and recruited enhancers underlie intestinal tumour initiation

    by Liam Gaynor, Harshabad Singh, Guodong Tie, Krithika Badarinath, Shariq Madha, Andrew Mancini, Swarnabh Bhattacharya, Mikio Hoshino, Frederic J. de Sauvage, Kazutaka Murata, et al.

    Oncogenic mutations that drive colorectal cancer can be present in healthy intestines for long periods without overt consequence1,2. Mutation of Adenomatous polyposis coli (Apc), the most common initiating event in conventional adenomas3, activates Wnt signalling, hence conferring fitness on mutant intestinal stem cells (ISCs)4,5. Apc mutations may occur in ISCs that arose by routine self-renewal or by dedifferentiation of their progeny. Although ISCs of these different origins are fundamentally similar6,7, it is unclear if both generate tumours equally well in uninjured intestines. Also unknown is whether cis-regulatory elements are substantively modulated upon Wnt hyperactivation or as a feature of subsequent tumours. Here, we show in two mouse models that adenomas are not an obligatory outcome of Apc deletion in either ISC source but require proximity of mutant intestinal crypts. Reduced crypt density abrogates, and aggregation of mutant colonic crypts augments, adenoma formation. Moreover, adenoma-resident ISCs open chromatin at thousands of enhancers that are inaccessible in Apc-null ISCs not associated with adenomas. These cis-elements explain adenoma-selective gene activity and persist, with little further expansion of the repertoire, as other oncogenic mutations accumulate. Thus, cooperativity between neighbouring mutant crypts and new accessibility at specific enhancers are key steps early in intestinal tumourigenesis.


  • Open Access

    Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma

    by Giuseppe Tarantino, Cora A. Ricker, Annette Wang, William Ge, Tyler J. Aprati, Amy Y. Huang, Shariq Madha, Jiajia Chen, Yingxiao Shi, Marc Glettig, et al.

    The introduction of immune checkpoint blockade (ICB) has markedly improved outcomes for advanced melanoma. However, many patients develop resistance through unknown mechanisms. While combination ICB has improved response rate and progression-free survival, it substantially increases toxicity. Biomarkers to distinguish patients who would benefit from combination therapy versus aPD-1 remain elusive. We analyzed whole-exome sequencing of pretreatment tumors from four cohorts ( n = 140) of ICB-naïve patients treated with aPD-1. High genomic heterogeneity and low ploidy robustly identified patients intrinsically resistant to aPD-1. To establish clinically actionable predictions, we optimized and validated a predictive model using ploidy and heterogeneity to confidently identify (90% PPV) patients with intrinsic resistance to and worse survival on aPD-1. We further observed that three of seven (43%) patients predicted to be intrinsically resistant to single-agent PD-1 ICB responded to combination ICB, suggesting that these patients may benefit disproportionately from combination ICB. These findings highlight the importance of heterogeneity and ploidy, nominating an approach toward clinical actionability.


  • Adaptation of pancreatic cancer cells to nutrient deprivation is reversible and requires glutamine synthetase stabilization by mTORC1

    by Pei-Yun Tsai, Min-Sik Lee, Unmesh Jadhav, Insia Naqvi, Shariq Madha, Ashley Adler, Meeta Mistry, Sergey Naumenko, Caroline A. Lewis, Daniel S. Hitchcock, et al.

    Significance: Pancreatic ductal adenocarcinoma (PDA) is a highly lethal malignancy with no effective therapies. PDA aggressiveness partly stems from its ability to grow within a uniquely dense stroma restricting nutrient access. This study demonstrates that PDA clones that survive chronic nutrient deprivation acquire reversible nongenetic adaptations allowing them to switch between metabolic states optimal for growth under nutrient-replete or nutrient-deprived conditions. One contributing factor to this adaptation is mTORC1 activation, which stabilizes glutamine synthetase (GS) necessary for glutamine generation in nutrient-deprived cancer cells. Our findings imply that although total GS levels may not be a prognostic marker for aggressive disease, GS inhibition is of high therapeutic value, as it targets specific cell clusters adapted to nutrient starvation, thus mitigating tumor growth.


  • Top Cited Papers

    Distinct Mesenchymal Cell Populations Generate the Essential Intestinal BMP Signaling Gradient

    by Neil McCarthy, Elisa Manieri, Elaine E. Storm, Assieh Saadatpour, Adrienne M. Luoma, Varun N. Kapoor, Shariq Madha, Liam T. Gaynor, Christian Cox, Shilpa Keerthivasan, et al.


  • Top Cited Papers

    Ascl2-Dependent Cell Dedifferentiation Drives Regeneration of Ablated Intestinal Stem Cells

    by Kazutaka Murata, Unmesh Jadhav, Shariq Madha, Johan van Es, Justin Dean, Alessia Cavazza, Kai Wucherpfennig, Franziska Michor, Hans Clevers, Ramesh A. Shivdasani


  • Open Access

    Adaptation of pancreatic cancer cells to nutrient deprivation is reversible and requires glutamine synthetase stabilization by mTORC1

    by Pei-Yun Tsai, Min-Sik Lee, Unmesh Jadhav, Insia Naqvi, Shariq Madha, Ashley Adler, Meeta Mistry, Sergey Naumenko, Caroline A. Lewis, Daniel S. Hitchcock, et al.

    Pancreatic ductal adenocarcinoma (PDA) is a lethal, therapy-resistant cancer that thrives in a highly desmoplastic, nutrient-deprived microenvironment. Several studies investigated the effects of depriving PDA of either glucose or glutamine alone. However, the consequences on PDA growth and metabolism of limiting both preferred nutrients have remained largely unknown. Here, we report the selection for clonal human PDA cells that survive and adapt to limiting levels of both glucose and glutamine. We find that adapted clones exhibit increased growth in vitro and enhanced tumor-forming capacity in vivo . Mechanistically, adapted clones share common transcriptional and metabolic programs, including amino acid use for de novo glutamine and nucleotide synthesis. They also display enhanced mTORC1 activity that prevents the proteasomal degradation of glutamine synthetase (GS), the rate-limiting enzyme for glutamine synthesis. This phenotype is notably reversible, with PDA cells acquiring alterations in open chromatin upon adaptation. Silencing of GS suppresses the enhanced growth of adapted cells and mitigates tumor growth. These findings identify non-genetic adaptations to nutrient deprivation in PDA and highlight GS as a dependency that could be targeted therapeutically in pancreatic cancer patients. Significance: Pancreatic ductal adenocarcinoma (PDA) is a highly lethal malignancy with no effective therapies. PDA aggressiveness partly stems from its ability to grow within a uniquely dense stroma restricting nutrient access. This study demonstrates that PDA clones that survive chronic nutrient deprivation acquire reversible non-genetic adaptations allowing them to switch between metabolic states optimal for growth under nutrient-replete or nutrient-deprived conditions. One contributing factor to this adaptation mTORC1 activation, which stabilizes glutamine synthetase (GS) necessary for glutamine generation in nutrient-deprived cancer cells. Our findings imply that although total GS levels may not be a prognostic marker for aggressive disease, GS inhibition is of high therapeutic value, as it targets specific cell clusters adapted to nutrient starvation, thus mitigating tumor growth.

  • Replicational Dilution of H3K27me3 in Mammalian Cells and the Role of Poised Promoters

    by Unmesh Jadhav, Elisa Manieri, Kodandaramireddy Nalapareddy, Shariq Madha, Shaon Chakrabarti, Kai Wucherpfennig, Megan Barefoot, Ramesh A. Shivdasani


  • Extensive Recovery of Embryonic Enhancer and Gene Memory Stored in Hypomethylated Enhancer DNA

    by Unmesh Jadhav, Alessia Cavazza, Kushal K. Banerjee, Huafeng Xie, Nicholas K. O’nEill, Veronica Saenz-Vash, Zachary Herbert, Shariq Madha, Stuart H. Orkin, Huili Zhai, et al.


  • Open Access

    Enhancer, transcriptional, and cell fate plasticity precedes intestinal determination during endoderm development

    by Kushal K. Banerjee, Madhurima Saxena, Namit Kumar, Lei Chen, Alessia Cavazza, Natalie H. Toke, Nicholas K. O'NEill, Shariq Madha, Unmesh Jadhav, Michael P. Verzi, et al.

    After acquiring competence for selected cell fates, embryonic primordia may remain plastic for variable periods before tissue identity is irrevocably determined (commitment). We investigated the chromatin basis for these developmental milestones in mouse endoderm, a tissue with recognizable rostro–caudal patterning and transcription factor (TF)-dependent interim plasticity. Foregut-specific enhancers are as accessible and active in early midgut as in foregut endoderm, and intestinal enhancers and identity are established only after ectopic cis-regulatory elements are decommissioned. Depletion of the intestinal TF CDX2 before this cis element transition stabilizes foregut enhancers, reinforces ectopic transcriptional programs, and hence imposes foregut identities on the midgut. Later in development, as the window of chromatin plasticity elapses, CDX2 depletion weakens intestinal, without strengthening foregut, enhancers. Thus, midgut endoderm is primed for heterologous cell fates, and TFs act on a background of shifting chromatin access to determine intestinal at the expense of foregut identity. Similar principles likely govern other fate commitments.